PL1691833T3 - Kompozycje zawierające polipeptydy - Google Patents
Kompozycje zawierające polipeptydyInfo
- Publication number
- PL1691833T3 PL1691833T3 PL04803302T PL04803302T PL1691833T3 PL 1691833 T3 PL1691833 T3 PL 1691833T3 PL 04803302 T PL04803302 T PL 04803302T PL 04803302 T PL04803302 T PL 04803302T PL 1691833 T3 PL1691833 T3 PL 1691833T3
- Authority
- PL
- Poland
- Prior art keywords
- polypeptide
- binding sites
- polypeptides
- antigen binding
- compositions
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 8
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 8
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 8
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000000427 antigen Substances 0.000 abstract 5
- 102000036639 antigens Human genes 0.000 abstract 5
- 108091007433 antigens Proteins 0.000 abstract 5
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03027511 | 2003-11-28 | ||
| EP04803302A EP1691833B1 (en) | 2003-11-28 | 2004-11-26 | Compositions comprising polypeptides |
| PCT/EP2004/013445 WO2005052004A2 (en) | 2003-11-28 | 2004-11-26 | Compositions comprising polypeptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1691833T3 true PL1691833T3 (pl) | 2010-08-31 |
Family
ID=34626385
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL04803302T PL1691833T3 (pl) | 2003-11-28 | 2004-11-26 | Kompozycje zawierające polipeptydy |
Country Status (18)
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5825756B2 (ja) | 2006-08-14 | 2015-12-02 | ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． | Ｃｄ１９を標的とする最適化抗体 |
| AU2007294575B2 (en) * | 2006-09-08 | 2013-06-27 | Viela Bio, Inc. | Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| US9308257B2 (en) * | 2007-11-28 | 2016-04-12 | Medimmune, Llc | Protein formulation |
| US8658765B2 (en) | 2009-12-31 | 2014-02-25 | Avidbiotics Corp. | Non-natural MIC proteins |
| US8796420B2 (en) | 2009-12-31 | 2014-08-05 | Avidbiotics Corp. | Non-natural MIC proteins |
| ES2675299T3 (es) | 2010-10-27 | 2018-07-10 | Amgen Research (Munich) Gmbh | Medios y métodos para el tratamiento del LDLBG |
| JP6130307B2 (ja) | 2011-03-17 | 2017-05-17 | ザ ユニバーシティ オブ バーミンガム | 再指向性免疫療法 |
| AU2012245260B2 (en) | 2011-04-22 | 2016-09-08 | Aptevo Research And Development Llc | Prostate-specific membrane antigen binding proteins and related compositions and methods |
| GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| JP6841656B2 (ja) | 2013-12-17 | 2021-03-10 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合アンタゴニスト及びタキサンを使用する癌の治療方法 |
| US20150210772A1 (en) | 2013-12-17 | 2015-07-30 | Genentech, Inc. | Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody |
| TWI742423B (zh) | 2014-05-29 | 2021-10-11 | 美商宏觀基因股份有限公司 | 特異性結合多種癌症抗原的三特異性結合分子和其使用方法 |
| CA2966573A1 (en) | 2014-11-05 | 2016-05-12 | Genentech, Inc. | Methods of producing two chain proteins in bacteria |
| RU2705274C2 (ru) | 2014-11-05 | 2019-11-06 | Дженентек, Инк. | Способы получения двуцепочечных белков в бактериях |
| WO2016126611A1 (en) | 2015-02-02 | 2016-08-11 | The University Of Birmingham | Targeting moiety peptide epitope complexes having a plurality of t-cell epitopes |
| CN108064170B (zh) | 2015-05-29 | 2022-07-15 | 豪夫迈·罗氏有限公司 | 癌症中pd-l1启动子甲基化 |
| EP3310815A1 (en) | 2015-06-17 | 2018-04-25 | F. Hoffmann-La Roche AG | Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes |
| JP7002446B2 (ja) | 2015-09-21 | 2022-03-04 | アプティーボ リサーチ アンド デベロップメント エルエルシー | Ｃｄ３結合ポリペプチド |
| AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
| ES2873846T5 (en) | 2015-11-19 | 2025-06-23 | Revitope Ltd | Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells |
| EP3178848A1 (en) | 2015-12-09 | 2017-06-14 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies |
| CN108290954B (zh) | 2015-12-09 | 2022-07-26 | 豪夫迈·罗氏有限公司 | Ii型抗cd20抗体用于降低抗药物抗体形成 |
| AU2017205089B2 (en) | 2016-01-08 | 2023-10-05 | F. Hoffmann-La Roche Ag | Methods of treating CEA-positive cancers using PD-1 axis binding antagonists and anti-CEA/anti-CD3 bispecific antibodies |
| CA3059010A1 (en) | 2016-06-02 | 2018-12-06 | F. Hoffmann-La Roche Ag | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
| EP3252078A1 (en) | 2016-06-02 | 2017-12-06 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
| US11046776B2 (en) | 2016-08-05 | 2021-06-29 | Genentech, Inc. | Multivalent and multiepitopic antibodies having agonistic activity and methods of use |
| JP7250674B2 (ja) | 2016-08-08 | 2023-04-03 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | がんの治療及び診断方法 |
| CN117752798A (zh) | 2016-12-19 | 2024-03-26 | 豪夫迈·罗氏有限公司 | 用靶向性4-1bb(cd137)激动剂的组合疗法 |
| MX2019006954A (es) | 2016-12-20 | 2019-08-01 | Hoffmann La Roche | Terapia de combinacion de anticuerpos biespecificos anti-cd20/anti-cd3 y agonistas de 4-1bb (cd137). |
| AU2018359506A1 (en) | 2017-11-01 | 2020-04-23 | F. Hoffmann-La Roche Ag | Combination therapy with targeted OX40 agonists |
| CN119074915A (zh) | 2018-03-13 | 2024-12-06 | 豪夫迈·罗氏有限公司 | 4-1bb激动剂与抗cd20抗体的治疗剂组合 |
| TWI841551B (zh) | 2018-03-13 | 2024-05-11 | 瑞士商赫孚孟拉羅股份公司 | 使用靶向4-1bb (cd137)之促效劑的組合療法 |
| EP3802617A4 (en) * | 2018-06-07 | 2022-04-27 | Cullinan Oncology, Inc. | MULTI-SPECIFIC BINDING PROTEINS AND METHODS OF USE THEREOF |
| CA3111809A1 (en) | 2018-09-21 | 2020-03-26 | Genentech, Inc. | Diagnostic methods for triple-negative breast cancer |
| SG11202104104VA (en) | 2018-11-05 | 2021-05-28 | Genentech Inc | Methods of producing two chain proteins in prokaryotic host cells |
| WO2020221792A1 (en) | 2019-04-30 | 2020-11-05 | Amgen Research (Munich) Gmbh | Means and methods of treating burkitt lymphoma or leukemia |
| KR102503349B1 (ko) | 2019-05-14 | 2023-02-23 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| PE20220568A1 (es) | 2019-05-21 | 2022-04-20 | Novartis Ag | Moleculas de union a cd19 y usos de las mismas |
| WO2021252917A2 (en) | 2020-06-11 | 2021-12-16 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| KR20230025691A (ko) | 2020-06-16 | 2023-02-22 | 제넨테크, 인크. | 삼중 음성 유방암을 치료하기 위한 방법과 조성물 |
| KR102453073B1 (ko) * | 2020-08-14 | 2022-10-11 | 건국대학교 글로컬산학협력단 | 피키아 파스토리스를 이용한 이중특이적 항체의 제조방법 및 이에 따른 이중특이적 항체 |
| US20240101673A1 (en) | 2021-02-03 | 2024-03-28 | Mozart Therapeutics, Inc. | Binding agents and methods of using the same |
| CN117279664A (zh) | 2021-04-10 | 2023-12-22 | 普方生物制药美国公司 | Folr1结合剂、其偶联物及其使用方法 |
| CA3216459A1 (en) | 2021-04-23 | 2022-10-27 | Profoundbio Us Co. | Anti-cd70 antibodies, conjugates thereof and methods of using the same |
| EP4083061A1 (en) * | 2021-04-30 | 2022-11-02 | Kilometro Rosso SPA | Fusion proteins and use thereof in the treatment of membranous nephropathy |
| TW202244059A (zh) | 2021-04-30 | 2022-11-16 | 瑞士商赫孚孟拉羅股份公司 | 用抗ｃｄ２０／抗ｃｄ３雙特異性抗體進行治療之給藥 |
| MX2023012408A (es) | 2021-04-30 | 2023-10-31 | Hoffmann La Roche | Dosis para tratamiento conjunto con anticuerpo biespecifico anti-cd20/anti-cd3 y conjugado anticuerpo farmaco anti-cd79b. |
| TW202320857A (zh) | 2021-07-06 | 2023-06-01 | 美商普方生物製藥美國公司 | 連接子、藥物連接子及其結合物及其使用方法 |
| WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
| IL314211A (en) | 2022-03-23 | 2024-09-01 | Genentech Inc | Combined treatment of bispecific antibody and chemotherapy against CD20/ANTI-CD3 |
| JP7701982B2 (ja) | 2022-04-13 | 2025-07-02 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 抗ｃｄ２０／抗ｃｄ３二重特異性抗体の薬学的組成物及び使用方法 |
| WO2024030956A2 (en) | 2022-08-03 | 2024-02-08 | Mozart Therapeutics, Inc. | Cd39-specific binding agents and methods of using the same |
| CN120152989A (zh) | 2022-11-03 | 2025-06-13 | 豪夫迈·罗氏有限公司 | 抗cd19/抗cd28双特异性抗体的组合疗法 |
| WO2024243423A1 (en) | 2023-05-24 | 2024-11-28 | Mozart Therapeutics, Inc. | Cd8-specific binding proteins and methods of using the same |
| WO2024261013A1 (en) | 2023-06-21 | 2024-12-26 | F. Hoffmann-La Roche Ag | Combination therapy with fap-targeted lymphotoxin beta receptor agonists |
| US20250115680A1 (en) | 2023-09-26 | 2025-04-10 | Profoundbio Us Co. | Ptk7 binding agents, conjugates thereof and methods of using the same |
| WO2025137344A1 (en) | 2023-12-20 | 2025-06-26 | Bristol-Myers Squibb Company | Antibodies targeting il-18 receptor beta (il-18rβ) and related methods |
| WO2025149661A1 (en) | 2024-01-10 | 2025-07-17 | Genmab A/S | Slitrk6 binding agents, conjugates thereof and methods of using the same |
| WO2025181219A1 (en) | 2024-02-29 | 2025-09-04 | Genmab A/S | Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| DE3853515T3 (de) | 1987-05-21 | 2005-08-25 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung. |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| AU664030B2 (en) | 1991-02-27 | 1995-11-02 | Micromet Ag | Serine-rich peptide linkers |
| US5525491A (en) | 1991-02-27 | 1996-06-11 | Creative Biomolecules, Inc. | Serine-rich peptide linkers |
| US5656730A (en) * | 1995-04-07 | 1997-08-12 | Enzon, Inc. | Stabilized monomeric protein compositions |
| TR200003087T2 (tr) * | 1998-04-21 | 2001-02-21 | Micromet Ag | Yeni CD19 X CD3 Spesifik polipeptidler ve kullanımları |
| US20020142964A1 (en) * | 2000-11-02 | 2002-10-03 | Nissen Torben Lauesgaard | Single-chain polypeptides |
| EP1441589B1 (en) * | 2001-11-08 | 2012-05-09 | Abbott Biotherapeutics Corp. | Stable liquid pharmaceutical formulation of igg antibodies |
-
2004
- 2004-11-26 PL PL04803302T patent/PL1691833T3/pl unknown
- 2004-11-26 EP EP10155222A patent/EP2186527A1/en not_active Withdrawn
- 2004-11-26 ES ES04803302T patent/ES2341252T3/es not_active Expired - Lifetime
- 2004-11-26 SI SI200431360T patent/SI1691833T1/sl unknown
- 2004-11-26 AT AT04803302T patent/ATE459374T1/de active
- 2004-11-26 CA CA2544532A patent/CA2544532C/en not_active Expired - Lifetime
- 2004-11-26 DE DE602004025840T patent/DE602004025840D1/de not_active Expired - Lifetime
- 2004-11-26 AU AU2004293182A patent/AU2004293182B2/en not_active Expired
- 2004-11-26 DK DK04803302.1T patent/DK1691833T3/da active
- 2004-11-26 EP EP04803302A patent/EP1691833B1/en not_active Expired - Lifetime
- 2004-11-26 US US10/580,660 patent/US10000574B2/en active Active
- 2004-11-26 PT PT04803302T patent/PT1691833E/pt unknown
- 2004-11-26 WO PCT/EP2004/013445 patent/WO2005052004A2/en active Application Filing
-
2010
- 2010-05-27 CY CY20101100465T patent/CY1110689T1/el unknown
-
2016
- 2016-05-03 NL NL300807C patent/NL300807I2/nl unknown
- 2016-05-05 HU HUS1600019C patent/HUS1600019I1/hu unknown
- 2016-05-05 CY CY2016010C patent/CY2016010I1/el unknown
- 2016-05-10 BE BE2016C023C patent/BE2016C023I2/fr unknown
- 2016-05-11 LU LU93067C patent/LU93067I2/fr unknown
- 2016-05-20 FR FR16C1000C patent/FR16C1000I2/fr active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US10000574B2 (en) | 2018-06-19 |
| WO2005052004A3 (en) | 2006-03-09 |
| ES2341252T3 (es) | 2010-06-17 |
| BE2016C023I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2023-12-18 |
| DE602004025840D1 (de) | 2010-04-15 |
| AU2004293182A1 (en) | 2005-06-09 |
| CA2544532C (en) | 2015-06-16 |
| CY2016010I2 (el) | 2016-08-31 |
| CY2016010I1 (el) | 2016-08-31 |
| EP2186527A1 (en) | 2010-05-19 |
| US20070249529A1 (en) | 2007-10-25 |
| NL300807I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2016-10-13 |
| LU93067I2 (fr) | 2016-07-11 |
| EP1691833A2 (en) | 2006-08-23 |
| SI1691833T1 (sl) | 2010-06-30 |
| EP1691833B1 (en) | 2010-03-03 |
| CA2544532A1 (en) | 2005-06-09 |
| HUS1600019I1 (hu) | 2016-06-28 |
| WO2005052004A2 (en) | 2005-06-09 |
| DK1691833T3 (da) | 2010-05-03 |
| ATE459374T1 (de) | 2010-03-15 |
| AU2004293182B2 (en) | 2010-02-18 |
| FR16C1000I2 (fr) | 2017-02-03 |
| PT1691833E (pt) | 2010-06-08 |
| CY1110689T1 (el) | 2015-06-10 |
| FR16C1000I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2016-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS1600019I1 (hu) | Polipeptideket tartalmazó készítmények | |
| WO2003011895A8 (en) | Compositions and methods for modulation of immune responses | |
| CY1118951T1 (el) | Χρηση αντισωματων υποδοχεα ιντερλευκινης-4 και συνθεσεις αυτων | |
| CY2019029I1 (el) | Anti-tnf αντισωματα, συνθεσεις, μεθοδοi και χρησεις | |
| UA89017C2 (uk) | ЛЮДСЬКЕ АНТИТІЛО, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ЛЮДСЬКИМ TNFSF13b | |
| PT1639011E (pt) | Anticorpos (dab) de domínio único peguilados | |
| ZA200404626B (en) | Modified anti-TNF alpha antibody. | |
| NZ553701A (en) | Composition comprising SC03-014 and SC03-022 antibodies against SARS-CoV | |
| CY1112993T1 (el) | Παραγοντες ειδικης δεσμευσης της αγγειοποιητινης-2 και της αγγειοποιητινης-1 | |
| PL2314623T3 (pl) | Przeciwciała wiążące il-1 beta i ich fragmenty | |
| WO2004020404A3 (en) | Modified transferin-antibody fusion proteins | |
| NZ503763A (en) | Antigenic compositions and vaccines comprising a high molecular weight (HMW) protein of Clamydia for therapeutic and prophylactic use | |
| WO2004020595A3 (en) | Novel human polypeptides encoded by polynucleotides | |
| PT1546734E (pt) | Anticorpos monoclonais de amiloide beta n 11 truncados, composições, métodos e utilizações | |
| WO2006023420A3 (en) | Integrin antagonists with enhanced antibody dependent cell-mediated cytotoxicity activity | |
| IL200373A (en) | A monoclonal antibody that binds to 3erbb and a pharmacological preparation that includes the same to inhibit 3erbb signaling in humans | |
| JP2002533123A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| WO2002096948A3 (en) | Engineered tetravalent antibodies and methods of use | |
| WO2007071692A3 (en) | Immunogenic composition | |
| WO2002036625A3 (en) | Prokineticin polypeptides, related compositions and methods | |
| WO2005028618A3 (en) | Immunogenic compositions for streptococcus agalactiae | |
| WO2004096989A3 (en) | Single chain antigen-binding polypeptides for polymer conjugation | |
| AU2002365269A8 (en) | Mut-il-18 or mut-il-18r proteins, antibodies, compositions, methods and uses | |
| EP1691664A4 (en) | ANTIBODIES AND / OR THEIR CONJUGATES BINDING TO THE AMINOTERMINAL FRAGMENT OF UROKINASE, COMPOSITIONS AND THEIR USES | |
| WO2002076406A3 (en) | Antibodies against autoantigens of primary biliary cirrhosis and methods of making and using them |